Particle.news

Download on the App Store

Biocon Secures CDSCO Approval for Generic Liraglutide

The biotech firm plans to roll out the Victoza equivalent rapidly through local commercialization partners to address India’s rising diabetes burden.

Image
Image

Overview

  • The Drugs Controller General of India cleared Biocon’s Liraglutide drug substance alongside Biocon Pharma’s 6 mg/ml pre-filled pen and cartridge product.
  • The approval covers the generic version of Victoza for treating insufficiently controlled Type 2 diabetes in adults, adolescents and children aged 10 and above.
  • Chief Executive Siddharth Mittal called the nod a major step toward expanding patient access to GLP-1 therapy in India.
  • India’s diabetes population exceeds 77 million and continues to grow, highlighting urgent demand for affordable treatments.
  • Following the approval announcement, Biocon shares climbed 0.81 percent to Rs 336.75 on the BSE.